Comparative Pharmacology
Head-to-head clinical analysis: METHADONE HYDROCHLORIDE versus METHADONE MOUD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHADONE HYDROCHLORIDE versus METHADONE MOUD.
METHADONE HYDROCHLORIDE vs Methadone (MOUD)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; also NMDA receptor antagonist and serotonin/norepinephrine reuptake inhibitor.
Methadone is a mu-opioid receptor agonist with high affinity. It also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and maintenance effects.
Oral: 20-30 mg daily for induction, then 20-120 mg daily for maintenance; IV: 2.5-10 mg every 8-12 hours for acute pain, titrated; IM/SC: same as IV. Frequency: daily for maintenance, every 8-12 hours for pain.
Initial: 20-30 mg orally once daily, titrated to effect. Maintenance: 10-120 mg orally once daily. Route: oral (tablet, liquid). Frequency: once daily.
None Documented
None Documented
Terminal half-life 24-36 hours (range 13-50 hours) for active l-isomer; clinical context: once-daily dosing possible but cautious due to prolonged QT interval risk.
Terminal elimination half-life: 24-36 hours following single dose; 13-50 hours with chronic dosing (due to tissue redistribution). Context: prolonged half-life supports once-daily dosing for opioid use disorder but requires careful titration to avoid accumulation.
Renal (80-90% as methadone and metabolites; ~30% unchanged), biliary/fecal (minor ~10%)
Primarily renal (20-40% as unchanged drug, with urine pH-dependent elimination; 50% as metabolites including EDDP and EMDP). Biliary/fecal excretion accounts for approximately 10-15%.
Category D/X
Category A/B
Opioid Agonist
Opioid Agonist